Free Trial
NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

Prothena logo
$7.72 -0.20 (-2.53%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$7.75 +0.03 (+0.34%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Prothena Stock (NASDAQ:PRTA)

Key Stats

Today's Range
$7.52
$7.98
50-Day Range
$4.59
$7.92
52-Week Range
$4.32
$23.66
Volume
1.09 million shs
Average Volume
958,914 shs
Market Capitalization
$415.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.25
Consensus Rating
Hold

Company Overview

Prothena Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

PRTA MarketRank™: 

Prothena scored higher than 59% of companies evaluated by MarketBeat, and ranked 456th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prothena has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Prothena has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Prothena's stock forecast and price target.
  • Earnings Growth

    Earnings for Prothena are expected to grow in the coming year, from ($4.04) to ($3.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prothena is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prothena is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prothena has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.25% of the float of Prothena has been sold short.
  • Short Interest Ratio / Days to Cover

    Prothena has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prothena has recently increased by 9.93%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Prothena does not currently pay a dividend.

  • Dividend Growth

    Prothena does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.25% of the float of Prothena has been sold short.
  • Short Interest Ratio / Days to Cover

    Prothena has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prothena has recently increased by 9.93%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Prothena has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Prothena this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    1 people have added Prothena to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Prothena insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of Prothena is held by insiders.

  • Percentage Held by Institutions

    97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Prothena's insider trading history.
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock News Headlines

Prothena (NASDAQ:PRTA) Receives Buy Rating from HC Wainwright
Royal Bank Of Canada Cuts Prothena (NASDAQ:PRTA) Price Target to $10.00
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
HC Wainwright Has Weak Forecast for Prothena FY2025 Earnings
9 Analysts Assess Prothena Corp: What You Need To Know
See More Headlines

PRTA Stock Analysis - Frequently Asked Questions

Prothena's stock was trading at $13.85 at the beginning of 2025. Since then, PRTA stock has decreased by 44.3% and is now trading at $7.72.

Prothena Corporation plc (NASDAQ:PRTA) posted its earnings results on Monday, August, 4th. The biotechnology company reported ($1.86) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by $0.75. The biotechnology company had revenue of $4.42 million for the quarter, compared to analyst estimates of $5.36 million. Prothena had a negative trailing twelve-month return on equity of 62.17% and a negative net margin of 2,929.30%.

Top institutional shareholders of Prothena include Acadian Asset Management LLC (1.89%), Nordea Investment Management AB (0.58%), Simplex Trading LLC and Monaco Asset Management SAM (0.13%). Insiders that own company stock include William P Scully, Gene G Kinney, Tran Nguyen, Dennis J Selkoe, Richard T Collier, Lars Ekman, Wagner M Zago, Michael J Malecek, Karin L Walker, Hideki Garren, Carol D Karp and Brandon S Smith.
View institutional ownership trends
.

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/04/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRTA
CIK
1559053
Employees
130
Year Founded
N/A

Price Target and Rating

High Price Target
$81.00
Low Price Target
$6.00
Potential Upside/Downside
+291.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$122.31 million
Net Margins
-2,929.30%
Pretax Margin
-2,530.46%
Return on Equity
-62.17%
Return on Assets
-54.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.68
Quick Ratio
9.00

Sales & Book Value

Annual Sales
$135.16 million
Price / Sales
3.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.03 per share
Price / Book
1.28

Miscellaneous

Outstanding Shares
53,830,000
Free Float
48,875,000
Market Cap
$415.57 million
Optionable
Optionable
Beta
-0.03
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:PRTA) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners